Hey #BayArea #LifeSciences friends! Join Siren Biotechnology, Inc.'s CEO, Dr. Nicole Paulk at the San Francisco Business Times Women Who Lead in Live Sciences event this Friday, March 15! 🚀 Register here: bizjournals.com/sanfrancisco/e…

"We're making the world's first #AAV #GeneTherapy for #oncology, and the worlds first Universal Gene Therapy that can be used to treat multiple indications" - Siren Biotechnology, Inc.'s CEO and Founder, Dr. Nicole Paulk on the latest 🎧 Venture Europe podcast. Listen in! Thanks for hosting us,

Watch Siren Biotechnology, Inc. CEO and Founder, Dr. Nicole Paulk discuss The Future of Medicine alongside Michael Severino (CEO, Tessera Therapeutics) and Geoffrey von Maltzahn (GP, Flagship Pioneering ) at The Montgomery Summit! Link below for full recording. youtube.com/watch?v=TISSpv…

Siren Biotechnology, Inc.’s CEO & Founder, Dr. Nicole Paulk, has joined the Biocom California Cell and #GeneTherapy Committee!

Siren Biotechnology, Inc.'s CEO Dr. Nicole Paulk spoke with immad and Rajat Suri of the Curiosity Podcast to talk about the future of #AAV #GeneTherapy. Listen in at the link below! curiositypodcast.substack.com/p/how-viral-ge…

Siren Biotechnology, Inc. is excited to welcome Chris Lovejoy to our Preclinical Research team! Chris brings a wealth of assay development expertise and will be a key player in advancing specialized assays for the development of our #AAV Immuno #GeneTherapies for #Cancer. Welcome to the team,

Headed to #ASGCT24? So are we! Find Siren Biotechnology, Inc. at these events to hear how we’re changing the game with #AAV Immuno #GeneTherapies for #Cancer. See you in Baltimore! ASGCT

The Siren Biotechnology, Inc. team has arrived in Baltimore for #ASGCT2024! Find us at one of our events to score a pair of this year’s epic #AAV #CatSocks. Tuesday, May 7 8:00-12:00 | Ballroom 3 AAV Manufacturing for CMC Success: Translating Preclinical Gene Therapy Products to Clinical

We’re excited to share Siren Biotechnology, Inc.'s vision for Universal #AAV Immuno #GeneTherapy at #ASGCT2024. Join us today 12:15-1:15 in room 324-326 to learn more! (Lunch and swag included 😺)

Siren Biotechnology, Inc. is excited to announce our partnership with Catalent Pharma for the manufacturing of our #AAV Immuno #GeneTherapies for #Cancer! Read more: globenewswire.com/news-release/2…

🚨 Sound the alarm, Siren Biotechnology, Inc. is #hiring in multiple departments! We’re looking for a Head of BD to lead our partnership and collaboration efforts, as well as a Preclinical Scientist (SRA/AS/Sci-I) to help advance our #AAV Immuno #GeneTherapy candidates to the clinic. For more

May is #BrainTumorAwarenessMonth. At Siren Biotechnology, Inc., we’re driven to make a transformative impact for patients with brain tumors with Universal AAV Immuno-Gene Therapy for Cancer. Let’s sound the alarm against #cancer! #BTAM #GrayMay

As #NationalBrainTumorAwareness month comes to a close, Siren Biotechnology, Inc. would like to invite our Bay Area colleagues to join us at the NorCal Brain Tumor Walk hosted by the National Brain Tumor Society on June 8 at the San Francisco Zoo. We’re excited to show our support of the #BrainTumor community!

How do you actually universalize an AAV? The key, Dr. Nicole Paulk says, is local delivery — and having a payload that doesn’t change with each new indication. 👈 Learn more about how Siren Biotechnology, Inc. is building a universal #AAV #GeneTherapy for #cancer in this recent Cell&Gene

On #GBMDay 2024, Siren Biotechnology, Inc. unites with patients and their families who are living with #glioblastoma every day. We’re driven to help those who face difficult-to-treat tumors like GBM with Universal #AAV Immuno #GeneTherapy. Let’s sound the alarm against #cancer!

We’re thrilled to announce that Siren Biotechnology, Inc.’s proposal for #SXSW2025 is in the running, and we need your support to make it happen! Our session will dive into the cutting-edge world of viral #GeneTherapy where scientists transform #viruses into powerful, engineerable tools for

Siren Biotechnology, Inc. is thrilled to have been awarded a Beckman Coulter Life Sciences SPRI Grant for Genomic Research to support the development of our Universal #AAV Immuno #GeneTherapy for #cancer!

👇 Tune in tomorrow! Siren Biotechnology, Inc.'s VP of Vector Development, Dr. Nathalie Clement, will join other industry experts to discuss #AAV #GeneTherapy #manufacturing with Thermo Fisher. Register at the link below! workcast.com/register?cpak=…